introduct
infect
lead
caus
morbid
mortal
patient
multipl
myeloma
epidemiolog
risk
factor
outcom
viral
respiratori
tract
infect
vrti
well
describ
patient
multipl
myeloma
manag
novel
agent
current
standard
care
method
patient
myeloma
test
posit
respiratori
viru
multiplex
polymeras
chain
reaction
clinic
radiolog
microbiolog
record
review
fourth
european
confer
infect
leukaemia
definit
rti
appli
univari
multivari
regress
analysi
risk
factor
perform
use
vrti
evalu
outcom
result
patient
test
posit
total
vrti
episod
patient
receiv
thalidomid
lenalidomid
bortezomib
combin
myeloma
therapi
median
three
treatment
regimen
vrti
occur
commonli
patient
progress
diseas
receipt
three
line
myeloma
therapi
associ
increas
risk
vrti
p
amongst
key
respiratori
pathogen
influenza
associ
highest
hospit
admiss
rate
icu
admiss
rate
mortal
whilst
rsv
associ
prolong
hospit
stay
conclus
patient
multipl
myeloma
advanc
diseas
manag
multipl
line
therapi
risk
vrti
target
intervent
preventiontreat
requir
multipl
myeloma
clonal
plasma
cell
malign
increas
frequenc
annual
estim
incid
per
develop
world
infect
lead
caus
mortal
patient
myeloma
increas
risk
due
diseas
treatmentrel
factor
treatment
myeloma
undergon
paradigm
shift
use
newer
immunomodulatori
drug
imid
eg
thalidomid
lenalidomid
proteasom
inhibitor
pi
eg
bortezomib
standard
care
shift
evid
chang
epidemiolog
infect
patient
myeloma
toward
predomin
viral
infect
includ
respiratori
tract
infect
rti
whilst
epidemiolog
clinic
outcom
risk
factor
associ
viral
rti
vrti
well
known
haematopoiet
stem
cell
transplant
hsct
set
support
appropri
manag
guidelin
characterist
report
myeloma
patient
manag
novel
agent
object
studi
describ
epidemiolog
risk
factor
outcom
vrti
patient
patient
identifi
retrospect
chemotherapi
drug
dispens
microbiolog
databas
use
follow
criteria
confirm
diagnosi
multipl
myeloma
receiv
activ
therapi
imid
pi
test
posit
respiratori
viral
rv
infect
nucleic
acid
amplif
test
nat
peter
maccallum
cancer
centr
pmcc
januari
decemb
clinic
record
elig
patient
review
use
standard
tool
captur
follow
patient
demograph
myeloma
therapi
season
infect
radiolog
chang
clinic
featur
outcom
length
stay
lo
requir
intens
care
icu
manag
allcaus
mortal
day
influenza
vaccin
gener
perform
commun
practition
vaccin
record
therefor
avail
evalu
studi
definit
rti
consist
previous
describ
fourth
european
confer
infect
leukaemia
brief
upper
respiratori
tract
infect
urti
defin
detect
rv
larynx
urti
diseas
urtid
defin
detect
rv
upper
respiratori
tract
fluid
specimen
togeth
symptom
andor
sign
lower
rti
diseas
lrtid
defin
clinic
symptom
pulmonari
infiltr
togeth
identif
rv
respiratori
secret
confirm
case
respiratori
tract
infect
diseas
rtid
defin
presenc
clinic
laboratori
criteria
detect
rv
month
initi
specimen
associ
onset
new
symptom
defin
new
infect
episod
studi
period
admit
patient
clinic
featur
upper
rti
routin
manag
singl
room
droplet
contact
precaut
pend
outcom
diagnost
workup
studi
period
patient
myeloma
receiv
treatment
consist
intern
practic
includ
autolog
hsct
asct
elig
patient
approv
clinic
trial
studi
novel
myeloma
therapi
includ
thalidomid
lenalidomid
bortezomib
use
combin
dexamethason
without
lowdos
cyclophosphamid
studi
diseas
period
patient
myeloma
defin
follow
induct
period
time
initi
diagnosi
cycl
initi
treatment
asct
period
includ
time
myeloabl
chemotherapi
eg
melphalan
day
post
stem
cell
reinfus
mainten
period
stabl
paraprotein
level
without
myeloma
treatment
progress
period
rise
paraprotein
level
necessit
chang
treatment
regimen
recommenc
treatment
chemotherapeut
agent
use
singli
combin
obtain
maintain
myeloma
diseas
respons
defin
line
therapi
studi
period
decis
perform
method
diagnost
evalu
vrti
direct
treat
clinician
sampl
analys
victorian
infecti
diseas
refer
laboratori
rv
nat
respiratori
multitub
multiplex
pcr
perform
target
respiratori
multiplex
pcr
includ
influenza
b
c
virus
parainfluenza
virus
pv
respiratori
syncyti
virus
rsv
b
coronavirus
hku
sar
adenovirus
picornavirus
enterovirus
rhinoviru
group
b
c
human
metapneumoviru
hmpv
includ
detect
panel
characterist
patient
vrti
summaris
proport
outcom
categor
variabl
compar
use
fisher
exact
test
univari
multivari
regress
analysi
risk
factor
patient
age
asct
receipt
bortezomib
number
line
chemotherapi
perform
use
vrti
evalu
outcom
covari
includ
model
univari
analysi
demonstr
p
analys
perform
use
stata
version
statacorp
inc
texa
usa
deem
statist
signific
human
research
ethic
committe
institut
approv
retrospect
studi
patient
myeloma
manag
studi
period
test
posit
total
vrti
episod
infect
rate
infect
per
patient
year
patient
myeloma
constitut
patient
malign
manag
pmcc
test
posit
rv
pharyng
swab
common
method
sampl
follow
close
pool
nasopharyng
swab
bronchoalveolar
lavag
patient
vrti
median
age
year
interquartil
rang
year
male
igg
myeloma
intern
stage
system
stage
diagnosi
patient
receiv
thalidomid
lenalidomid
bortezomib
combin
myeloma
therapi
median
three
treatment
regimen
major
patient
receiv
asct
vrti
episod
associ
hypogammaglobulinaemia
requir
intraven
immunoglobulin
replac
demograph
myeloma
characterist
studi
popul
summaris
tabl
episod
upper
rti
urti
confirm
urt
infecti
diseas
urtid
confirm
lrtid
viral
rti
occur
commonli
diseas
progress
episod
requir
hospit
admiss
median
lo
day
interquartil
rang
day
overal
icu
admiss
rate
allcaus
mortal
rate
day
key
viral
pathogen
influenza
vrti
observ
occur
patient
mainten
treatment
diseas
progress
major
influenza
vrti
episod
lrtid
episod
associ
hospit
admiss
median
lo
day
influenza
rti
also
associ
highest
icu
admiss
allcaus
mortal
rate
respect
seven
influenza
episod
treat
oseltamivir
rsv
episod
associ
hospit
admiss
instanc
median
lo
day
rsv
episod
urtid
rsv
rti
associ
icu
admiss
instanc
allcaus
mortal
record
day
rsv
episod
treat
ribavirin
except
one
patient
concurr
rsv
influenza
receiv
oseltamivir
ribavirin
frequenc
vrti
episod
myeloma
characterist
infect
site
outcom
accord
key
rv
pathogen
summar
tabl
univari
regress
analysi
demonstr
age
year
p
receipt
asct
bortezomib
p
three
line
myeloma
therapi
p
associ
vrti
tabl
multivari
logist
regress
analysi
demonstr
receipt
three
line
therapi
independ
associ
increas
risk
vrti
p
epidemiolog
clinic
featur
outcom
associ
vrti
well
describ
hsct
set
particular
follow
allogen
hsct
knowledg
first
dedic
studi
vrti
patient
myeloma
manag
contemporari
treatment
includ
novel
myeloma
therapi
asct
strength
studi
fact
inpati
outpati
studi
found
vrti
occur
patient
manag
myeloma
occur
frequent
patient
progress
diseas
addit
found
receipt
asct
bortezomib
three
line
therapi
risk
factor
vrti
univari
analysi
sever
possibl
explan
find
vrti
innat
immun
system
initi
host
antivir
respons
via
intracellular
signal
pathway
releas
interferon
cytokin
cytokin
includ
augment
host
n
number
iqr
interquartil
rang
asct
autolog
stem
cell
transplant
iss
intern
stage
system
ivig
intraven
immunoglobulin
regimen
prior
onset
viral
respiratori
tract
infect
antivir
respons
activ
adapt
immun
system
play
key
role
subsequ
viral
clearanc
corticosteroid
treatment
myeloma
reduc
monocyt
count
function
traffick
area
need
whilst
imid
reduc
monocyt
activ
also
bortezomib
disrupt
impact
viral
antigen
present
addit
patient
myeloma
diseaserel
immun
deficit
includ
defect
cellmedi
humer
immun
accumul
progress
diseas
addit
patient
myeloma
known
lower
level
specif
influenza
antibodi
compar
healthi
control
factor
may
explain
observ
multipl
line
treatment
risk
factor
vrti
progress
diseas
risk
period
demonstr
vrti
associ
morbid
patient
myeloma
nearli
vrti
episod
requir
hospit
admiss
median
lo
day
influenza
infect
particular
associ
poor
outcom
increas
use
resourc
found
two
third
influenza
vrti
associ
hospit
admiss
major
influenza
episod
involv
lrtid
substanti
higher
report
previou
studi
predominantli
allogen
hsct
patient
influenza
episod
associ
highest
proport
icu
admiss
allcaus
mortal
rate
amongst
rv
pathogen
mortal
rate
influenza
lrtid
patient
haematolog
malign
hsct
report
fact
patient
advanc
myeloma
mayb
higher
risk
group
complic
patient
hsct
demonstr
recent
pandem
patient
myeloma
requir
icu
manag
patient
malign
studi
highlight
need
awar
rv
infect
amongst
myeloma
patient
subgroup
high
risk
complic
identifi
prevent
measur
treatment
evalu
patient
myeloma
reduc
morbid
mortal
associ
influenza
infect
rate
oseltamivir
treatment
cohort
may
contribut
observ
mortal
earli
treatment
influenza
episod
oseltamivir
shown
improv
outcom
season
influenza
vaccin
well
toler
effect
result
reduc
number
urti
episod
hospitalis
albeit
studi
undertaken
current
treatment
regimen
institut
current
nation
immunis
intern
consensu
guidelin
recommend
annual
season
influenza
vaccin
patient
myeloma
australian
guidelin
recommend
two
dose
month
apart
patient
previous
vaccin
respiratori
syncyti
virus
pose
concern
clinician
manag
patient
haematolog
malign
observ
similar
rate
rsv
patient
cohort
compar
studi
rsv
episod
popul
associ
modest
icu
admiss
rate
mortal
contrast
expect
mortal
rate
rsv
lrti
predominantli
allogen
hsct
patient
popul
lo
remain
substanti
day
research
requir
role
antivir
treatment
ribavirin
patient
popul
studi
sever
limit
retrospect
cohort
studi
use
posit
viral
result
identifi
case
therefor
decis
perform
diagnost
evalu
vrti
determin
treat
physician
like
select
bia
favour
symptomat
unwel
patient
addit
patient
mild
infect
may
present
local
practition
specif
indic
icu
admiss
attribut
caus
death
determin
lack
verifi
vaccin
histori
meant
unabl
evalu
impact
season
influenza
vaccin
rate
outcom
influenza
vrti
cohort
dedic
studi
vrti
patient
myeloma
manag
novel
agent
asct
identifi
receipt
multipl
line
therapi
risk
factor
vrti
diseas
progress
risk
period
vrti
particular
influenza
vrti
associ
morbid
mortal
highlight
import
prevent
measur
eg
earli
treatment
vaccin
need
research
treatment
patient
myeloma
